
OSTX Stock Forecast & Price Target
OSTX Analyst Ratings
Bulls say
OS Therapies Inc has demonstrated a robust outlook, particularly in the veterinary oncology market, which is projected to expand significantly from $1.58 billion in 2024 to $4.77 billion by 2034, indicating strong demand for its targeted immunotherapies. The company is advancing its OST-HER2 Phase 2b program, with encouraging two-year survival data and a favorable safety profile, suggesting potential for positive regulatory approval. Management's successful discussions with NYSE representatives and potential investors further solidify expectations for an enhanced market presence, driven by a coordinated operational strategy within the animal health sector.
Bears say
OS Therapies Inc reported a substantial net operating loss of $6.9 million for the third quarter of 2025, equating to a loss of $0.21 per share. This ongoing financial strain is attributed to the continued investment in its listeria-based cancer immunotherapy programs, specifically OST-HER2. The significant losses raise concerns about the company's financial sustainability and its ability to attract further investment or achieve profitability in the near term.
This aggregate rating is based on analysts' research of OS Therapies Inc and is not a guaranteed prediction by Public.com or investment advice.
OSTX Analyst Forecast & Price Prediction
Start investing in OSTX
Order type
Buy in
Order amount
Est. shares
0 shares